nature portfolio

Corresponding author(s):	Karen Miga
Last updated by author(s):	Jul 2, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

< ∙	トつ	+	ıctı	CC
.)	ıa	u	isti	I ()

Fora	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
	X A stateme	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statist	ical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.			
\boxtimes	A descript	ion of all covariates tested			
\boxtimes	A descript	ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
	A full desc	ription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
	For null hy	pothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted as as exact values whenever suitable.			
\boxtimes	For Bayesi	an analysis, information on the choice of priors and Markov chain Monte Carlo settings			
\boxtimes	For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
\boxtimes	Estimates	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated			
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
Sof	ftware an	d code			
Polic	cy information a	about <u>availability of computer code</u>			
Da	ita collection	All code used to collect data are cited in github links and citations of the manuscript			

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

All code used to analyzes the data are cited in github links and citations of the manuscript

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All raw sequence data used in this study is available at the following HPRC Github: https://github.com/human-pangenomics/HG002_Data_Freeze_v1.0. The final HPRC-HG002 curated assemblies are available in NCBI under the BioProject IDs PRJNA794175 and PRJNA794172, with accession numbers GCA_021951015.1 and GCA_021950905.1, for the maternal and paternal haplotypes respectively.

Human research	participants
----------------	--------------

Authentication

Genome sequence authentication

riairiair resca	ii cii pai ti	cipants		
Policy information al	bout <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.		
Reporting on sex and gender		The biological sex (male and female) of the samples used have been noted, as our goal was to include genome sequencing and assembly of both X and Y sex chromosomes.		
Population characteristics		The population that the individuals are from (Ashkenazi, African American) have been noted, and approved in the original informed consents.		
Recruitment		Participants were recruited in separate studies from this study		
Ethics oversight		Personal Genome Project (HG002) and Washington University (HG06807)		
Note that full informati	ion on the appr	oval of the study protocol must also be provided in the manuscript.		
Field-spe	<u>cific re</u>	porting		
Please select the one	e below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	В	Behavioural & social sciences		
For a reference copy of the	e document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
<u>Life scien</u>	ces sti	udy design		
All studies must disc	lose on these	points even when the disclosure is negative.		
	No sample size estimate was necessary. This is a high-quality reference genome sequencing project, focused on one individual as representative of the species. The variation that exist within humans is not expected to dramatically change the outcome of the findings.			
Data exclusions	No data were excluded from the analyses			
Replication	Most algorithm	Most algorithms applied in this study were repeated two or more times on the same sample		
Randomization	Randomization	andomization is not applicable to this genome assembly study, as there is a sample size of one individual.		
Blinding	Blinding is not applicable, as there are not any quantifications that are subjective.			
	C			
Reporting	g tor sp	pecific materials, systems and methods		
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	erimental s	ystems Methods		
n/a Involved in the	study	n/a Involved in the study		
Antibodies		ChIP-seq		
Eukaryotic co		Flow cytometry		
	gy and archaeo			
	other organism	15		
Clinical data	aarch of conco			
MI Dual use les	earch of concer	"		
Eukaryotic ce	ell lines			
Policy information al	bout <u>cell lines</u>	and Sex and Gender in Research		
Cell line source(s)		GM24385 (RRID:CVCL_1C78) EBV-immortalized lymphoblastoid cell line (LCL) of HG002		

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)

None detected in the genome data

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.